Home›Companies›Healthcare›OxyDial

OxyDial Inc

Develops blood testing equipment and software for researchers and medical professionals.

Updated Nov 10, 2026·Latest SEC filing May 20, 2026·Suggest an edit

About OxyDial

OxyDial is a private company based in Philadelphia, Pennsylvania, incorporated in 2022 in Delaware. It has reported $700,000 raised in one offering on Form D since May 2026. Its chief executive is Oleksandr Shestakov.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Mar 17, 2026May 20, 2026$700,000of $1.5M target8$87,500EquityRule 506(b)Form D ↗

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on OxyDial's Form D filed May 20, 2026.

Oleksandr Shestakov
Oleksandr Shestakov
Co-Founder and CEO, director
AA
Alexey Aprelev
Executive officer and director
DA
David Albert
Director
JY
John Yapaola
Director
Also a chief executive officer and director at Wyng.

Sources

  1. SECOxyDial Inc filing history
  2. CompanyOxyDial privacy policy
  3. CompanyOxyDial contact
  4. CompanyOxyDial mission